# Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

> **NCT03793426** · — · TERMINATED · sponsor: **Octapharma** · enrollment: 7 (actual)

## Conditions studied

- Congenital Fibrinogen Deficiency

## Interventions

- **BIOLOGICAL:** Fibryga

## Key facts

- **NCT ID:** NCT03793426
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-28
- **Primary completion:** 2025-05-14
- **Final completion:** 2025-05-14
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** FORMA-07 was initiated as a requirement imposed by the U.S. FDA as part of Octapharma's regulatory obligations. After approving Fibryga for treatment of acquired fibrinogen deficiency in 2024, FDA has agreed that the study may now be discontinued.
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793426, "Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03793426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*